Pfizer’s Celebrex Gets Timely Boost From NIH Alzheimer’s Trial

Celecoxib shows no increased cardiovascular risk in patients taking the drug for up to three years in an Alzheimer’s prevention study. NIH halts all treatment in the trial due to a naproxen safety signal and difficulty getting patients to use celecoxib following negative safety data in a colon polyp study.